Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Oral and intramuscular methylprednisolone are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.[L10785,L10788] Intra-articular and soft tissue injections are indicated for short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L10788] Intralesional injections are indicated for alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.[L10788]
Marketing Status approved; vet_approved
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 72647-331; 0781-5022; 80425-0230; 59746-003; 59762-0049; 63187-160; 71205-453; 0603-4593; 82094-402; 60722-1003; 64958-0084; 55289-649; 59762-4440; 63629-2218; 68001-557; 68001-560; 80425-0242; 22552-0029; 0009-0056; 45865-104; 59762-0050; 59762-0051; 60760-373; 63187-802; 65162-871; 68071-5221; 70121-1000; 59746-015; 65162-982; 68001-005; 68071-4028; 68084-149; 68788-4593; 71205-054; 72189-264; 82094-401; 45865-417; 50090-3094; 59746-002; 63629-2433; 68001-558; 68180-686; 69306-400; 70518-3622; 82094-403; 59746-001; 68071-2301; 68180-687; 70518-2982; 70771-1348; 70771-1349; 80425-0255; 0009-0073; 49999-153; 53002-3120; 63629-2226; 68001-559; 68180-685; 68180-688; 68382-917; 68382-918; 68382-919; 70771-1350; 80425-0231; 0904-6914; 49452-4686; 51552-0603; 0009-0020; 42806-400; 65162-984; 68180-689; 68382-916; 68788-8276; 69306-004; 70121-1001; 70771-1351; 76420-041; 82298-118; 76420-193; 82094-404; 82094-405; 51927-0201; 0009-0022; 65162-980; 68071-2745; 68788-7833; 0009-0038; 57582-011; 0009-0176; 57582-101
UNII X4W7ZR7023
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.000406%
Abnormal faeces07.01.03.0010.000070%Not Available
Abscess11.01.08.001--Not Available
Acne23.02.01.001--Not Available
Acute abdomen07.01.06.0150.000032%Not Available
Acute hepatic failure09.01.03.0010.000032%Not Available
Acute psychosis19.03.01.0010.000032%Not Available
Acute respiratory distress syndrome24.03.02.034; 10.02.01.067; 22.01.03.0010.000176%
Addison's disease10.04.08.008; 05.01.02.006; 14.11.01.0250.000032%Not Available
Adrenal insufficiency14.11.01.004; 05.01.02.0010.000192%
Adrenocortical insufficiency acute05.01.02.005; 14.11.01.0200.000032%Not Available
Affective disorder19.04.04.0010.000032%Not Available
Ageusia17.02.07.001; 07.14.03.0030.000141%Not Available
Aggression19.05.01.0010.000128%Not Available
Agitation19.06.02.001; 17.02.05.0120.000617%
Agranulocytosis01.02.03.0010.000064%Not Available
Alanine aminotransferase increased13.03.04.005--
Alkalosis14.01.02.001--
Alkalosis hypokalaemic14.01.02.002--Not Available
Altered state of consciousness19.07.01.003; 17.02.04.0010.000144%Not Available
Amenorrhoea21.01.02.001; 05.05.01.002--
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Anal fissure07.03.01.002--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000950%
Anaphylactic shock24.06.02.004; 10.01.07.0020.000847%Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anger19.04.02.0010.000233%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene